Skip to main content

Table 2 IC50 values and sensitization ratio of conventional chemotherapeutic drugs and its combinations with MF towards human colorectal cancer cell lines SW1116 and SW837

From: Methylferulate from Tamarix aucheriana inhibits growth and enhances chemosensitivity of human colorectal cancer cells: possible mechanism of action

Single and combined treatment with chemotherapeutic drugs and MF

SW1116

IC50 (M)a

Sensitization ratiob

Pc values

CPT (128× 10−11- 1× 10−4 M)

2.0 × 10−5

-

 

CPT (128× 10−11 - 1× 10−4 M) + MF (1.5 mM)

21 × 10−8

95.0

0.025

5FU (89.6× 10−10- 0.7× 10−3 M)

8.83 × 10−6

-

 

5FU (89.6× 10−10- 0.7× 10−3 M) + MF (1.5 mM)

84 × 10−10

1051

0.025

DOX (110× 10−12 - 0.86× 10−5 M)

0.43 × 10−4

-

 

DOX (110× 10−12 - 0.86× 10−5) + MF (1.5 mM)

3.44 × 10−7

125

0.081

TAX (94× 10−11- 1.47× 10−4 M)

1.47 × 10−4

-

 

TAX (94× 10−11- 1.47× 10−4 M) + MF (1.5 mM)

5.72 × 10−6

26

0.183

VBL (3.84× 10−11 - 0.03× 10−4 M)

0.22 × 10−8

-

 

VBL (3.84× 10−11 - 0.03× 10−4 M) + MF (1.5 mM)

3.52 × 10−11

62.55

0.326

VCR (3.84× 10−11 - 0.03× 10−4 M)

0.4 × 10−8

-

 

VCR (3.84× 10−11 - 0.03× 10−4 M) + MF (1.5 mM)

3.15 × 10−11

254

0.079

ETP (5.12× 10−10 - 0.04× 10−3M)

1.19 × 10−6

-

 

ETP (5.12× 10−10 - 0.04× 10−3M) + MF (1.5 mM)

5.4 × 10−10

2204

0.026

ELP (2.56× 10−10 - 0.02× 10−3M)

0.06 × 10−4

-

 

ELP (2.56× 10−10 - 0.02× 10−3M) + MF (1.5 mM)

1.3 × 10−9

4615

0.001

AMS (1.28× 10−10- 0.01× 10−3M)

0.013 × 10−3

-

 

AMS (1.28× 10−10- 0.01× 10−3M) + MF (1.5 mM)

0.2 × 10−7

650

0.001

HHG (25.6× 10−12 – 0.2× 10−5M)

2.0 × 10−7

-

 

HHG (25.6× 10−12 – 0.2× 10−5M) + MF (1.5 mM)

3 × 10−9

67

0.010

Single and combined treatment with chemotherapeutic drugs and MF

SW837

IC50 (M)a

Sensitization ratiob

Pc values

CPT (128× 10−11- 1× 10−4 M)

5 × 10−5

-

 

CPT (128 × 10−11- 1× 10−4 M) + MF (1.5 mM)

4 × 10−6

12.5

0.012

5FU (89.6× 10−10- 0.7× 10−3 M)

0.7 × 10−3

-

 

5FU (89.6× 10−10- 0.7× 10−3 M) + MF (1.5 mM)

2.6 × 10−5

269

0.001

DOX (110× 10−12 - 0.86× 10−5 M)

3.44 × 10−6

-

 

DOX (110× 10−12 - 0.86× 10−5) + MF (1.5 mM)

27.5 × 10−8

12.5

0.005

TAX (94× 10−11- 1.47× 10−4 M)

1.47 × 10−4

-

 

TAX (94× 10−11- 1.47× 10−4 M) + MF (1.5 mM)

5.86 × 10−6

25

0.045

VBL (3.84× 10−11 - 0.03× 10−4 M)

0.11 × 10−6

-

 

VBL (3.84× 10−11 - 0.03× 10−4 M) + MF (1.5 mM)

0.44 × 10−8

25

0.060

VCR (3.84× 10−11 - 0.03× 10−4 M)

0.2 × 10−7

-

 

VCR (3.84× 10−11 - 0.03× 10−4 M) + MF (1.5 mM)

2.4 × 10−9

8.33

0.119

ETP (5.12× 10−10 - 0.04× 10−3M

0.18 × 10−4

-

 

ETP (5.12× 10−10 - 0.04× 10−3M) + MF (1.5 mM)

0.51 × 10−6

35

0.003

ELP (2.56× 10−10 - 0.02× 10−3M)

0.02 × 10−3

-

 

ELP (2.56× 10−10 - 0.02× 10−3M) + MF (1.5 mM)

0.32 × 10−7

625

0.001

HHG (25.6× 10−12 – 0.2× 10−5M)

0.6 × 10−6

-

 

HHG (25.6× 10−12 – 0.2× 10−5M) + MF (1.5 mM)

2.25 × 10−8

27

0.012

  1. aThe data are based on the mean of absorbance measurements from three independent experiments
  2. bSensitization ration = IC50 of drug / IC50 of drug + MF
  3. cP Value for the combined treatment with drug and MF vs. drug alone